A Phase Ⅰ, Multi-center, Open-label, Single-arm, Dose Escalation, First-in-human Clinical Study of HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs HY-0102 (Primary)
Indications Colorectal cancer; Head and neck cancer; Liver cancer; Lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Shanghai HyaMab Biotech

12 Mar 2024 Status changed from active, no longer recruiting to completed.
20 Oct 2023 Planned primary completion date changed from 30 May 2023 to 30 Dec 2023.
24 Apr 2023 Planned primary completion date changed from 30 Mar 2023 to 30 May 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com